Myasthenia gravis management involves enhancement of acetylcholine availability within the NMJ via inhibition of cholinesterase enzymes, or immunosuppression/immunomodulation (Farmakidis et al., 2018). This evidence concerns the gene BCHE and myasthenia gravis.